Aug 31, 2022

Featuring perspectives from Prof Jonathan Ledermann, including the following topics:

• Introduction (0:00)
• Case: An Asian woman in her early 80s with ovarian cancer and a gBRCA mutation receiving maintenance olaparib after surgery and adjuvant chemotherapy — Rao Mushtaq, MD (2:05)
• Journal Club with Prof Ledermann (7:58)
• Case: A woman in her mid 80s with gBRCA wild-type high-grade serous ovarian cancer (HGSOC) who develops recurrent disease after declining maintenance niraparib — Priya Rudolph, MD, PhD (17:28)
• Antibody-Drug Conjugates for Ovarian Cancer (23:09)
• Case: A woman in her mid 70s with HGSOC and gBRCA1 and 2 mutations who responds to olaparib for 5 years but then develops progressive disease after stopping — Karim ElSahwi, MD (33:38)
• Case: A woman in her late 60s with gBRCA wild-type Stage IIIC ovarian cancer who receives IV/IP adjuvant chemotherapy — Gigi Chen, MD (43:19)
• Case: A woman in her mid 40s with microsatellite instability-high BRCA wild-type clear cell ovarian cancer with stable disease on pembrolizumab — Syed F Zafar, MD (47:59)
• Case: A woman in her late 50s with recurrent BRCA wild-type (HRp) low-grade ovarian cancer with rising CA-125, pleural effusion and a new lung nodule on salvage chemotherapy — Dana M Chase, MD (52:48)
• Case: A woman in her early 90s with past medical history of untreated chronic lymphocytic leukemia who presents with Stage III/IV ovarian cancer — Rajalaxmi McKenna, MD (56:45)

CME information and select publications